Incretin Atlas·MoleculesTrialsOutcomesTimelinePipelineAboutMedical Adviser's Group
Incretin Atlas › Trials › VISTA (NCT06579092)

VISTA (NCT06579092)

AZD5004 (ECC5004) · obesity

Data cut 12 November 2026 · page built 16 November 2026

Design

Molecule(s)
AZD5004 (ECC5004)
Population
obesity
Phase
2
Participants
310
Duration
36 weeks
Registry
NCT06579092

Results by arm

ArmPopulationWeeksnWeight, efficacyWeight, treatment-policyHbA1c, ppAE discontinuation, %Any discontinuation, %Nausea, %Vomiting, %SAE, %SBP, mmHgStatus
5 mg QDobesity36310−2.7 % vs −0.6 %
Δ −2.1 pp
————————press release
15 mg QDobesity36310−6.5 % vs −0.6 %
Δ −5.9 pp
————————press release
50 mg QD (escalated every 4 weeks)obesity36310−9.2 % vs −0.6 %
Δ −8.6 pp
————————press release
75 mg QD (escalated weekly)obesity36310−11.8 % vs −0.6 %
Δ −11.2 pp
————————press release
75 mg QD (escalated every 2 weeks)obesity36310−11.1 % vs −0.6 %
Δ −10.5 pp
————————press release

Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.

Verbatim quotes from the source (5)
  • 5 mg QD · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 15 mg QD · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 50 mg QD (escalated every 4 weeks) · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 75 mg QD (escalated weekly) · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%
  • 75 mg QD (escalated every 2 weeks) · weight_eff · press release
    Week 36 | -2.7% | -6.5% | -9.2% | -11.8% | -11.1% | -0.3%

Primary sources

How to cite this page

Medical Adviser's Group. Incretin Atlas: VISTA (NCT06579092). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/vista/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.

Cite the primary publication for any single result; every value above links to it.